FDA Endorses Spruce's BLA Plan for TA-ERT; Submission on Track for Q4
SPRB has more than doubled off its 52-week low of $7.
Summary
Spruce completed two pre-BLA meetings with the FDA, which validated its manufacturing comparability strategy and aligned on the BLA content and format for TA-ERT in Sanfilippo Syndrome Type B. The company also completed the first PPQ batch in July and expects the second in Q4, keeping the BLA submission on track for Q4 2026. This follows the Q2 update that outlined the path to BLA, but today's news adds concrete FDA alignment and manufacturing progress. The accelerated approval pathway based on CSF HS-NRE reduction remains intact, with a confirmatory study allowed to start during review. For a $148M market cap company, this de-risks the regulatory path and supports the timeline for a potential first disease-modifying therapy in MPS IIIB.
At the time of this announcement, SPRB was trading at $51.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $148.2M. The 52-week trading range was $7.00 to $240.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.